PUBLIC COMPANY
save$MDGLMADRIGAL PHARMACEUTICALS, INC.
$MDGL499.40-0.06%West Conshohocken, PA, USupdated 2d ago
community read0 votes
pipeline
2
marketed
1
phase 3
0
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
1Marketed1Unknown
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
- phase2Study of Resmetirom in Children and Adolescents With MASH
- phase3A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
- phase2Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH
- —Rezdiffra Pregnancy and Lactation Registry
- phase2Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)
- phase2Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)
- phase1A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal Function
- phase3A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
🐶 Hiring Signal
News
- Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.Young biotechs usually get acquired instead of profitably selling their own medicines. A growing number are proving they can, which could make the sector more broadly appealing to investors, some say.biopharma_dive · 5mo ago
Data sources
last refreshed 54m ago
Found something off?
comments(0)
5-min edit window · permanent after that